223 related articles for article (PubMed ID: 17605732)
1. Minimizing the risk of recurrent or progressive invasive mold infections during stem cell transplantation or further intensive chemotherapy.
Grigg A; Slavin M
Transpl Infect Dis; 2008 Feb; 10(1):3-12. PubMed ID: 17605732
[TBL] [Abstract][Full Text] [Related]
2. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature.
Martino R; Lopez R; Sureda A; Brunet S; Domingo-Albós A
Haematologica; 1997; 82(3):297-304. PubMed ID: 9234575
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy.
Cornely OA; Aversa F; Cook P; Jones B; Michallet M; Shea T; Vallejo C
Eur J Haematol; 2011 Oct; 87(4):289-301. PubMed ID: 21752098
[TBL] [Abstract][Full Text] [Related]
4. Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation.
Michallet M; Ito JI
J Clin Oncol; 2009 Jul; 27(20):3398-409. PubMed ID: 19487382
[TBL] [Abstract][Full Text] [Related]
5. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents.
Strasfeld L; Weinstock DM
Expert Rev Anti Infect Ther; 2006 Jun; 4(3):457-68. PubMed ID: 16771622
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis.
Cornely OA; Böhme A; Reichert D; Reuter S; Maschmeyer G; Maertens J; Buchheidt D; Paluszewska M; Arenz D; Bethe U; Effelsberg J; Lövenich H; Sieniawski M; Haas A; Einsele H; Eimermacher H; Martino R; Silling G; Hahn M; Wacker S; Ullmann AJ; Karthaus M;
J Antimicrob Chemother; 2008 Apr; 61(4):939-46. PubMed ID: 18272515
[TBL] [Abstract][Full Text] [Related]
7. Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
Girmenia C; Barosi G; Aversa F; Bacigalupo A; Barbui T; Baronciani D; Bosi A; Candoni A; Locasciulli A; Locatelli F; Menichetti F; Musso M; Viscoli C; Rambaldi A
Clin Infect Dis; 2009 Oct; 49(8):1226-36. PubMed ID: 19772390
[TBL] [Abstract][Full Text] [Related]
8. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.
Maertens J
Eur J Haematol; 2007 Apr; 78(4):275-82. PubMed ID: 17241370
[TBL] [Abstract][Full Text] [Related]
9. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions.
Safdar A; Rodriguez GH; Lichtiger B; Dickey BF; Kontoyiannis DP; Freireich EJ; Shpall EJ; Raad II; Kantarjian HM; Champlin RE
Cancer; 2006 Jun; 106(12):2664-71. PubMed ID: 16691620
[TBL] [Abstract][Full Text] [Related]
10. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts.
Segal BH; Almyroudis NG; Battiwalla M; Herbrecht R; Perfect JR; Walsh TJ; Wingard JR
Clin Infect Dis; 2007 Feb; 44(3):402-9. PubMed ID: 17205448
[TBL] [Abstract][Full Text] [Related]
11. Prophylaxis, pre-emptive or empirical antifungal therapy: which is best in non-lung transplant recipients?
Salavert M
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S149-53. PubMed ID: 19013340
[TBL] [Abstract][Full Text] [Related]
12. Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: clinical implications of recent studies.
Marr KA
Curr Opin Infect Dis; 2008 Aug; 21(4):409-14. PubMed ID: 18594294
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for invasive fungal infections in haematopoietic stem cell transplantation.
Camps IR
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S119-23. PubMed ID: 19013335
[TBL] [Abstract][Full Text] [Related]
14. New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies.
Leather HL; Wingard JR
Blood Rev; 2006 Sep; 20(5):267-87. PubMed ID: 16781028
[TBL] [Abstract][Full Text] [Related]
15. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
Glasmacher A; Prentice AG
J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i23-i32. PubMed ID: 16120631
[TBL] [Abstract][Full Text] [Related]
16. Antifungal prophylaxis in adult stem cell transplantation and haematological malignancy.
Slavin MA; Heath CH; Thursky KA; Morrissey CO; Szer J; Ling LM; Milliken ST; Grigg AP
Intern Med J; 2008 Jun; 38(6b):468-76. PubMed ID: 18588520
[TBL] [Abstract][Full Text] [Related]
17. Management of fungal infections following allogeneic stem cell transplantation.
Narimatsu H; Kami M
Expert Rev Anti Infect Ther; 2008 Jun; 6(3):373-84. PubMed ID: 18588501
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients.
Barnes RA; White PL; Bygrave C; Evans N; Healy B; Kell J
J Clin Pathol; 2009 Jan; 62(1):64-9. PubMed ID: 19103864
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
Sohn HS; Lee TJ; Kim J; Kim D
Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
[TBL] [Abstract][Full Text] [Related]
20. Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation.
Roman E; Osunkwo I; Militano O; Cooney E; van de Ven C; Cairo MS
Pediatr Blood Cancer; 2008 Feb; 50(2):325-30. PubMed ID: 17514732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
